The study also examines the role of these pathways in breast cancer drug resistance and explores their potential as targets for cancer treatment, especially PARP inhibitors in HRD breast cancer. The gene discussed is PARP1; the disease is hypoparathyroidism-retardation-dysmorphism syndrome.